Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Spine Journal
Published in: European Spine Journal 10/2005

01-12-2005 | Original Article

Does raloxifene treatment influence back pain and disability among postmenopausal women with osteoporosis?

Authors: Georgios Papadokostakis, Pavlos Katonis, John Damilakis, Alexander Hadjipavlou

Published in: European Spine Journal | Issue 10/2005

Login to get access

Abstract

Clinical studies have suggested that postmenopausal women on estrogen replacement treatment are more likely to experience back pain and related disability compared to women who do not take estrogens. Raloxifene, a selective estrogen receptor modulator has estrogen-like effects on bone tissue, and antagonize the action of estrogens on endometrium and breast tissue. It is unknown if the treatment of osteoporosis with raloxifene has estrogen-like or opposite effects on back pain and functional capacity among postmenopausal women with osteoporosis. A total of 120 postmenopausal women with osteoporosis and chronic back pain were randomized to receive raloxifene 60 mg with 1,000 mg calcium, and 800 IU vitamin D daily or 1,000 mg calcium and 800 IU vitamin D daily. Pain intensity and pain-related disability were measured before treatment at 6 months and after 1 year. Repeated measures of ANOVA, did not reveal statistically significant differences over time, on pain intensity and disability scores, between groups studied. There was a trend in pain intensity changes during the follow-up period, but the differences between the groups were not statistically significant. It seems that treatment with raloxifene does not influence back pain and disability among postmenopausal women with osteoporosis. Raloxifene may have estrogenic agonist effects on nociceptive processing in the central nervous system.
Literature
1.
Ammann P, Rizzoli R (2003) Bone strength and its determinants. Osteoporos Int 14(3):13–18
2.
Boss SM, Huster WJ, Neild JA et al. (1997) Effects of raloxifene hydrocloride on the endometrium of pstmenopausal women. Am J Obstet Gynecol 177:1458–1464
3.
Boscainos PJ, Sapkas G, Stilianessi E et al. (2003) Greek versions of the Oswestry and Roland-Morris Disability Questionnaires. Clin Orthop 411:40–53
4.
Brynhildsen JO, Bjors E, Skarsgard C et al. (1998) Is hormone replacement therapy a risk factor for low back pain among postmenopausal women? Spine 23:809–813
5.
Chlebowski RT, Hendrix SL, Langer RD et al. (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women’s health initiative randomized trial. JAMA 289:3243–3253
6.
Cumming SR, Eckert S, Krueger KA et al. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 281:2189–2197
7.
Chudler EH, Dong WK (1955) The role of the basal ganglia in nociception and pain.Pain 60:3–38
8.
Cyr M, Landry M, Di Paolo T (2000) Modulation by estrogen-receptor directed drug of 5-hydroxytryptamine-2A receptors in rat brain. Neuropsychopharmacology 23:69–78
9.
Cyr M, Ghribi O, Thibault C et al. (2001) Ovarian steroids and selective estrogen receptor modulators activity on rat brain NMDA and AMPA receptors. Brain Res Rev 37:153–161
10.
Delmas PD, Bjarnason NH, Mitlak BH et al. (1997) Effects of raloxifene on bone mineral density serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641–1647
11.
Draper MW, Flowers DE, Huster WJ et al. (1997) A controlled trial of raloxifene (LY 139481) HCL : impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 11:835–842
12.
Duval P, Lenoir V, Moussaoui S et al. (1996) Substance P and neurokinin. A variations throughout the rat estrous cycle; comparison with ovariectomized and male rats: II. Trigeminal nucleus and cervical spinal cord. J Neurosci Res 45:610–616
13.
Ettinger B, Black DM, MitlakBH et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645
14.
Ferry S, Hannaford P, Warskyj M et al. (2000) Carpal tunnel syndrome: a nested case-control study of risk factors in women. Am J Epidemiol 151:566–574
15.
Fillingim RB (2002) Association between estrogen replacement therapy and back pain among postmenopausal women. Spine 27:332–334
16.
Florio P, Quirici B, Casarosa E et al. (2001) Neuroendocrine effects of raloxifene hydrochloride in postmenopausal women. Gynecol Endocrinol 15:359–366
17.
Gruber CJ, Tschugguel W, Schneeberger C et al. (2002) Production and actions of estrogens. N Engl J Med 346:340–352
18.
Hulley S, Grady D, Bush T et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS). JAMA 280:605–613
19.
Hapidou EG, De Catanzaro D (1998) Sensitivity to cold pressor pain in dysmenorrheic and non dysmenorrheic women as a function of menstrual cycle phase. Pain 34:277–283
20.
Heils A, Teufel A, Petri S et al. (1996) Allelic variation of human serotonin transporter gene expression. J Neurochem 66:2621–2624
21.
LeResche L, Saunders K, Von Korff MR et al (1997) Use of exogenous hormones and risk of temporomandibular disorder pain. Pain 69:153–160
22.
Kawata M, Yuri K, Morimoto M (1994) Steroid hormone effects on gene expression, neuronal structure, and differentiation. Horm Behav 28:477–482
23.
Kanis JA, Johnell O, Black DM et al. (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation Trial. Bone 33:293–300
24.
Landry M, Levesque D, Di Paolo T (2002) Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain.Neuroendocrinology 76:214–222
25.
Musgrave DS, Vogt MT, Nevitt MC et al. (2001) Back problems among postmenopausal women taking estrogen replacement therapy: the study of osteoporotic fractures. Spine 26:1606–1612
26.
McCloskey E, Spector TD, Eyres KS et al. (1993) The assessment of vertebral deformity. A method for use in population studies and clinical trials. Osteoporos Int 3:138–147
27.
Magnusson JE, Fisher K (2000) The involvement of dopamine in nociception: the role of D(1) and D(2) receptors in the dorsolateral striatum. Brain Res 855:260–266
28.
Ohara PT, Granato A, Moallem TM et al. (2003). Dopaminergic input to GABAergic neurons in the rostral agranular insular cortex of the rat. J Neurocytol 32:131–141
29.
Petrenko AB, Yamakura T, Baba H et al. (2003) The role of N-methyl-Daspartate (NMDA) receptors in pain: a review. Anesth Analg 97:1108–1116
30.
Quinones-Jenab V, Jenab S, Ogawa S et al. (1997) Estrogen regulation of mu-opioid receptor mRNA in the forebrain of female rats. Brain Res Mol 47:134–138
31.
Shukla R, Husain M, Tandon R et al. (2003) Platelet 3H ketanserin binding in tension-type headache. Headache 43:103–108
32.
Shumaker SA, Legault C, Rapp SR et al. (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the women’s health initiative memory study: a randomized controlled trial.JAMA 89:2651–2662
33.
Schwarz MJ, Spath M, Muller-Bardorff H et al. (1999) Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients. Neurosci Lett 259:196–198
34.
Sun YG, Lundeberg T, Yu LC (2003) Involvement of endogenous betaendorphin in antinociception in the arcuate nucleus of hypothalamus in rats with inflammation.Pain 104:55–63
35.
Von Korff M, Jensen MP, Karoly P (2000) Assessing global pain severity by self-report in clinical and health services research. Spine 25:3140–3151
36.
Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. (2003) Effect of estrogen plus progestin on stroke in postmenopausal women: the women’s health initiative: a randomized trial. JAMA 289:2673–2684
37.
Walsh BW, Kuller LH, Wild RA et al. (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279:1445–1451
Metadata
Title
Does raloxifene treatment influence back pain and disability among postmenopausal women with osteoporosis?
Authors
Georgios Papadokostakis
Pavlos Katonis
John Damilakis
Alexander Hadjipavlou
Publication date
01-12-2005
Publisher
Springer-Verlag
Published in
European Spine Journal / Issue 10/2005
Print ISSN: 0940-6719
Electronic ISSN: 1432-0932
DOI
https://doi.org/10.1007/s00586-005-0899-1

Other articles of this Issue 10/2005

European Spine Journal 10/2005 Go to the issue

Original Article

Health-related quality of life assessment by the EuroQol-5D can provide cost-utility data in the field of low-back surgery.

Original Article

Effects of unisegmental disc compression on adjacent segments: an in vivo animal model

Society News

SSE Update December 2005

Original Article

Transcostovertebral kyphoplasty of the mid and high thoracic spine

Announcements

December 2005

Author’s Reply

Controversies in failed back surgery syndrome (by B. Schaller)